Distinctive Attributes of Indian Patients With Classical BCR::ABL1 Negative Myeloproliferative Neoplasms: Unified Clinical and Laboratory Data

被引:2
作者
Singh, Suvir [1 ]
Singh, Jagdeep [2 ]
Mehta, Arpan [3 ]
Sharma, Rintu [1 ]
Joshi, Kaveri [1 ]
Jain, Kunal [2 ]
Paul, Davinder [2 ]
Oberoi, Gurleen [4 ]
Jindal, Nandita [5 ]
Dhillon, Barjinderjit [5 ]
Narang, Vikram [6 ]
机构
[1] Dayanand Med Coll & Hosp, Dept Clin Haematol & Stem Cell Transplantat, Ludhiana 141001, Punjab, India
[2] Dayanand Med Coll & Hosp, Dept Med Oncol, Ludhiana, India
[3] Neuberg Supratech Reference Labs, Ahmadabad, India
[4] All India Inst Med Sci, Dept Hematopathol, , India Ludhiana, New Delhi, India
[5] Dayanand Med Coll & Hosp, Dept Mol Genet, Ludhiana, India
[6] Dayanand Med Coll & Hosp, Dept Pathol, Ludhiana, India
关键词
Molecular; Myelofibrosis; Myeloproliferative; NGS; Polycythemia; Thrombosis; INTERNATIONAL WORKING GROUP; PRIMARY MYELOFIBROSIS; POLYCYTHEMIA-VERA; PROGNOSTIC MODEL; PREDICT SURVIVAL; MUTATIONS; DIAGNOSIS; VARIANTS; FEATURES; DISEASE;
D O I
10.1016/j.clml.2023.01.012
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
We report clinical and molecular features of Indian patients with BCR:ABL1 negative MPNs. A relatively lower symptom burden at diagnosis, younger age of onset and low burden of thrombosis indicates a comparatively indolent presentation. Several novel mutations on 1 of the largest NGS datasets in Indian patients are also reported. A summary of recommended considerations for clinical practice is provided. Introduction: We report one of the largest single center data from a mixed referral setting in India describing baseline characteristics and outcomes of patients with classical BCR::ABL1 negative myeloproliferative neoplasms (MPNs). Materials and Methods: Patients diagnosed from June 2019 to 2022 were included. Workup and treatment was as per current guidelines. Results: Diagnosis comprised polycythemia vera (PV) in 51(49%), ET in 33(31.7%) and prefibrotic primary myelofibrosis (MF) pre fibrotic myelofibrosis (prePMF) and myelofibrosis in 10(9.6%) patients each. Median age at diagnosis was 52 years for PV and ET, 65.5 for MF and 79 years for prePMF. Diagnosis was incidental in 63(56.7%) and after thrombosis in 8(7.2%) patients. Baseline next generation sequencing (NGS) was available for 63(60.5%) patients. Driver mutations in PV: JAK2 in 80.3%; in ET: JAK2 in 41%, CALR in 26%, MPL in 2.9%; in prePMF JAK2 in 70%, CALR in 20%, MPL in 10%, and in MF: JAK2 in 10%, MPL in 30% and CALR in 40%. Seven novel mutations were detected of which 5 were potentially pathogenic on computational analysis. After median follow up of 30 months, 2 patients had disease transformation and none had new episodes of thrombosis. Ten patients died, most commonly with cardiovascular events(n = 5,50%). Median overall survival was not reached. Mean OS time was 10.19 years(95%CI, 8.6 to 11.74) and mean time to transformation was 12.2 years(95% CI,11.8 to 12.6). Conclusion: Our data indicates comparatively indolent presentation of MPNs in India with younger age and lower risk of thrombosis. Further follow up will enable correlation with molecular data and guide modification of age based risk stratification models.
引用
收藏
页码:360 / 369.e1
页数:11
相关论文
共 50 条
[41]   Aberrant Activation-Inducec Cyticine Deaminase Gene Expression Links BCR/ABL1-Negative Classical Myeloproliferative Neoplasms [J].
Dermenci, Hasan ;
Aday, Aynur Daglar ;
Teker, Aysegul Basak Akadam ;
Hancer, Veysel Sabri ;
Gelmez, Metin Yusuf ;
Nalcaci, Meliha ;
Yavuz, Akif Selim .
HASEKI TIP BULTENI-MEDICAL BULLETIN OF HASEKI, 2022, 60 (03) :228-233
[42]   JAK2, CALR, and MPL Mutation Profiles in Colombian patients with BCR-ABL Negative Myeloproliferative Neoplasms [J].
Giraldo-Rincon, Ana Isabel ;
Molina, Sara Naranjo ;
Gomez-Lopera, Natalia ;
Acevedo, Daniel Aguirre ;
Benavidez, Andrea Ucroz ;
Cardenas, Kenny Galvez ;
Ambrosi, Francisco Cuellar ;
Torres, Jose Domingo ;
Ospina, Sigifredo ;
Palacio, Katherine ;
Jaramillo, Lina Gaviria ;
Muneton, Carlos Mario ;
Palacio, Gonzalo Vasquez .
COLOMBIA MEDICA, 2023, 54 (03)
[43]   Recent advances in the genomics and therapy of BCR/ABL1-positive and -negative chronic myeloproliferative neoplasms [J].
Mughal, Tariq I. ;
Gotlib, Jason ;
Mesa, Ruben ;
Koschmieder, Steffen ;
Khoury, H. Jean ;
Cortes, Jorge E. ;
Barbui, Tiziano ;
Hehlmann, Rudiger ;
Mauro, Michael ;
Saussele, Susanne ;
Radich, Jerald P. ;
Van Etten, Richard A. ;
Saglio, Giuseppe ;
Verstovek, Srdnan ;
Gale, Robert Peter ;
Abdel-Wahab, Omar .
LEUKEMIA RESEARCH, 2018, 67 :67-74
[44]   Chronic myeloproliferative neoplasms with concomitant CALR mutation and BCR::ABL1 translocation: diagnostic and therapeutic implications of a rare hybrid disease [J].
Zanelli, Magda ;
Fragliasso, Valentina ;
Loscocco, Giuseppe Gaetano ;
Sanguedolce, Francesca ;
Broggi, Giuseppe ;
Zizzo, Maurizio ;
Palicelli, Andrea ;
Ricci, Stefano ;
Ambrogi, Elisa ;
Martino, Giovanni ;
Aversa, Sara ;
Coppa, Francesca ;
Gentile, Pietro ;
Gozzi, Fabrizio ;
Caltabiano, Rosario ;
Koufopoulos, Nektarios ;
Asaturova, Aleksandra ;
Cimino, Luca ;
Cavazza, Alberto ;
Orcioni, Giulio Fraternali ;
Ascani, Stefano .
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY, 2024, 12
[45]   Upregulated SPAG6 correlates with increased STAT1 and is associated with reduced sensitivity of interferon-α response in BCR::ABL1 negative myeloproliferative neoplasms [J].
Ding, Li ;
Luo, Jie ;
Du, Juan ;
Zhao, Beibei ;
Luo, Jin ;
Pan, Shirui ;
Zhang, Linyi ;
Yan, Xinyu ;
Li, Junnan ;
Liu, Lin .
CANCER SCIENCE, 2023, 114 (11) :4445-4458
[46]   A Review of Clonal Relationships in Myeloproliferative Neoplasms With Co-Mutations of JAK2, CALR or MPL and BCR::ABL1 [J].
Noorafrooz, Mohammadamin ;
Ghods, Sanaz ;
Gale, Robert Peter ;
Noorafrooz, Ramin .
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2025, 25 (04) :249-253
[47]   JAK 2V617F Mutation: Frequency and Relation to Clinical and Laboratory Features of BCR-ABL Negative Myeloproliferative Diseases [J].
Ilhan, Gul ;
Karakus, Sema ;
Sahin, Feride I. .
UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI, 2012, 22 (02) :77-84
[48]   Concomitant BCR-ABL1 Translocation and JAK2V617F Mutation in Three Patients with Myeloproliferative Neoplasms [J].
Hummel, Jennifer M. ;
Kletecka, M. Carmen Frias ;
Sanks, Jennifer K. ;
Chiselite, Mihaela D. ;
Roulston, Diane ;
Smith, Lauren B. ;
Czuchlewski, David R. ;
Elenitoba-Johnson, Kojo S. J. ;
Lim, Megan S. .
DIAGNOSTIC MOLECULAR PATHOLOGY, 2012, 21 (03) :176-183
[49]   Mutation and Lineage Analysis of DNMT3A in BCR-ABL1-negative Chronic Myeloproliferative Neoplasms [J].
Lin, Huan-Chau ;
Wang, Shu-Ching ;
Chen, Caleb Gon-Shen ;
Chang, Ming-Chih ;
Wang, Wei-Ting ;
Su, Nai-Wen ;
Cheng, Hung-I ;
Lin, Johnson ;
Chang, Yi-Fang ;
Hsieh, Ruey-Kuen ;
Chang, Chien-Chung ;
Hwang, Yuchi ;
Lim, Ken-Hong ;
Kuo, Yuan-Yeh .
INTERNATIONAL JOURNAL OF GERONTOLOGY, 2013, 7 (03) :186-188
[50]   BCR-ABL1-Negative Chronic Myeloproliferative Neoplasms and Pulmonary Hypertension: A Prospective Long-Term Follow-up Study of the Impact of Pulmonary Hypertension on Survival [J].
Payzin, Kadriye Bahriye ;
Savasoglu, Kaan ;
Alacacioglu, Inci ;
Dalgic, Elif Ebru ;
Kucukzeybek, Betul Bolat ;
Calli, Aylin Orgen ;
Bener, Sadi ;
Payzin, Serdar .
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 (02) :125-131